- Reference code :
- wf339
- Published date :
-
29 August 2000
- Expired date :
-
15 January 2028
AstraZeneca has gained its first approval for Symbicort Turbuhalerv® , a new and innovative asthma treatment. Containing the corticosteroid budesonide and fast and long-acting bronchodilator formoterol in a single inhaler (Turbuhaler® ), Symbicort® is being hailed as a significant new step in the field of asthma management.
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
